J Prosthodont:钛基台和氧化锆基台植体的长期存活率对比

2019-07-30 不详 网络

本研究旨在评估钛种植体与氧化锆基台的长期种植体存活率,以及与全钛种植体相比,氧化锆基台种植体对边缘骨丧失(MBL)和探诊深度(PPD)的影响。研究人员检索包括Cochrane对照试验中心登记册,MEDLINE,EMBASE和中国生物医学文献数据库的电子数据库。纳入两种类型的研究:报告钛植入物与氧化锆基台的存活率,至少平均/中位随访5年的临床研究,以及报告与全钛植入物相比氧化锆基台植入物对MBL和P

本研究旨在评估钛种植体与氧化锆基台的长期种植体存活率,以及与全钛种植体相比,氧化锆基台种植体对边缘骨丧失(MBL)和探诊深度(PPD)的影响。

研究人员检索包括Cochrane对照试验中心登记册,MEDLINE,EMBASE和中国生物医学文献数据库的电子数据库。纳入两种类型的研究:报告钛植入物与氧化锆基台的存活率,至少平均/中位随访5年的临床研究,以及报告与全钛植入物相比氧化锆基台植入物对MBL和PPD影响的临床试验。两位评价员筛选并选择记录,评估质量,并独立提取纳入研究的数据。

结果,该评价包括来自18种出版物的16项研究。没有一项比较研究是在低偏倚风险的情况下进行评估的。具有氧化锆基台的植入物的整体存活率估计为96%(置信区间[CIs] [94%,98%],I2 = 0%)。氧化锆基台和全钛植入物相比,结果明显有利于具有氧化锆基台的植入物(MBL,平均差异[MD] = -0.09,CIs [-0.17,0.00],p = 0.05,I2 = 40 %; PPD,MD = -0.18,CIs [-0.32,-0.05],p = 0.008,I2 = 0%)。当修复体是植入物支撑的覆盖义齿而不是单个冠时,氧化锆基台的上述结果更加。

综上所述,该研究结果表明,与全钛植入物相比,具有氧化锆基台的植入物在种植体周围的健康状况上可具有可接受的性能;然而,在长期随访中,具有氧化锆基台的植入物的存活率略低于全钛植入物。

原始出处:

Cao Y, Yu C, et al., Long-Term Survival and Peri-Implant Health of Titanium Implants with Zirconia Abutments: A Systematic Review and Meta-Analysis. J Prosthodont. 2019 Jul 7. doi: 10.1111/jopr.13097.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1679804, encodeId=daf216e9804ce, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Sun Jan 26 09:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862952, encodeId=fdd21862952b6, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Nov 28 04:37:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364511, encodeId=faea13645111f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459762, encodeId=3b781459e622b, content=<a href='/topic/show?id=00da63996ea' target=_blank style='color:#2F92EE;'>#氧化锆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63996, encryptionId=00da63996ea, topicName=氧化锆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=facd6195692, createdName=medsci248, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602186, encodeId=d4fe1602186ec, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2020-01-26 30397613
  2. [GetPortalCommentsPageByObjectIdResponse(id=1679804, encodeId=daf216e9804ce, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Sun Jan 26 09:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862952, encodeId=fdd21862952b6, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Nov 28 04:37:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364511, encodeId=faea13645111f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459762, encodeId=3b781459e622b, content=<a href='/topic/show?id=00da63996ea' target=_blank style='color:#2F92EE;'>#氧化锆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63996, encryptionId=00da63996ea, topicName=氧化锆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=facd6195692, createdName=medsci248, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602186, encodeId=d4fe1602186ec, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1679804, encodeId=daf216e9804ce, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Sun Jan 26 09:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862952, encodeId=fdd21862952b6, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Nov 28 04:37:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364511, encodeId=faea13645111f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459762, encodeId=3b781459e622b, content=<a href='/topic/show?id=00da63996ea' target=_blank style='color:#2F92EE;'>#氧化锆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63996, encryptionId=00da63996ea, topicName=氧化锆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=facd6195692, createdName=medsci248, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602186, encodeId=d4fe1602186ec, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-01 医者仁心
  4. [GetPortalCommentsPageByObjectIdResponse(id=1679804, encodeId=daf216e9804ce, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Sun Jan 26 09:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862952, encodeId=fdd21862952b6, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Nov 28 04:37:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364511, encodeId=faea13645111f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459762, encodeId=3b781459e622b, content=<a href='/topic/show?id=00da63996ea' target=_blank style='color:#2F92EE;'>#氧化锆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63996, encryptionId=00da63996ea, topicName=氧化锆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=facd6195692, createdName=medsci248, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602186, encodeId=d4fe1602186ec, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1679804, encodeId=daf216e9804ce, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Sun Jan 26 09:37:00 CST 2020, time=2020-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862952, encodeId=fdd21862952b6, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Thu Nov 28 04:37:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364511, encodeId=faea13645111f, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459762, encodeId=3b781459e622b, content=<a href='/topic/show?id=00da63996ea' target=_blank style='color:#2F92EE;'>#氧化锆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63996, encryptionId=00da63996ea, topicName=氧化锆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=facd6195692, createdName=medsci248, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602186, encodeId=d4fe1602186ec, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Aug 01 12:37:00 CST 2019, time=2019-08-01, status=1, ipAttribution=)]
    2019-08-01 sunylz